Biological Treatment
We recommend
Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itching and…
Alopecia Areata – Autoimmune Inflammatory Disease and a New Targeted Treatment Option
Alopecia areata (AA) is one of the non-scarring focal alopecias. It is an autoimmune disease of the…
Articles on this topic
Safety Analysis of Baricitinib in Long-Term Treatment of Rheumatoid Arthritis
Janus kinase inhibitors are relatively new and very promising drugs, but their novelty also…
Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis
Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated…
Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis
Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in…
Direct Comparison of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis
The final results of the direct comparison of ixekizumab and adalimumab in the therapy of…
How do IL-17 and IL-23 inhibitors fare in the treatment of psoriasis in direct comparison?
A recent study published in the British Journal of Dermatology is only the second paper to…
Therapy Change from Adalimumab to Baricitinib in Patients with Rheumatoid Arthritis
The aim of the presented analysis of data from the RA-BEAM study was to evaluate the clinical…
Persistence of Treatment with Secukinumab and Ixekizumab in Patients with Moderate to Severe Psoriasis
Although IL-17 targeted drugs are increasingly used in the treatment of moderate to severe…
Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab
In patients with rheumatoid arthritis, pain and functional impairment may persist even with…
Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate
The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA)…
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Alopecia Areata – Autoimmune Inflammatory Disease and a New Targeted Treatment Option
- Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor
- How do IL-17 and IL-23 inhibitors fare in the treatment of psoriasis in direct comparison?
- New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
- Biological treatment of psoriatic arthritis in the 1st line – results of the SPIRIT-H2H study after 1 year of follow-up
- Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis
Journal on this topic
Related topic
Interesting links